170 related articles for article (PubMed ID: 29237537)
1. Metastatic cutaneous apocrine adenocarcinoma responsive to the programmed cell death protein 1 inhibitor pembrolizumab.
Rogatsch M; Schmid J; Lax S; Uranitsch M; Schmid-Zalaudek K; Giuffrida R; Zalaudek I
Eur J Cancer; 2018 Feb; 90():146-148. PubMed ID: 29237537
[No Abstract] [Full Text] [Related]
2. Metastatic Cutaneous Apocrine Adenocarcinoma Treated With a Combination of Pertuzumab-Based Targeted Therapy and Taxane Chemotherapy: A Case Report.
Otsuka M; Yamasaki O; Kaji T; Shien T; Iwatsuki K
JAMA Dermatol; 2016 Jan; 152(1):111-3. PubMed ID: 26375389
[No Abstract] [Full Text] [Related]
3. Exceptional response to anti-PD-1 treatment in a patient with metastatic cutaneous hidradenocarcinoma.
Obermann H; Schmidle P; Steimle-Grauer SA; Pfarr N; Posch C
Eur J Cancer; 2021 Mar; 145():143-145. PubMed ID: 33465705
[No Abstract] [Full Text] [Related]
4. Antitumor and Anti-Hepatitis C Viral Response After Administration of the Anti-Programmed Death 1 Antibody Pembrolizumab.
Jang S; Venna S
J Oncol Pract; 2017 Jul; 13(7):462-464. PubMed ID: 28562196
[No Abstract] [Full Text] [Related]
5. Pembrolizumab for classical Hodgkin's lymphoma.
Burki TK
Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
[No Abstract] [Full Text] [Related]
6. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
Owosho AA; Randazzo J; Rosen EB; Estilo CL; Huryn JM; Chi P; Yom SK
Oral Oncol; 2016 Dec; 63():e1-e3. PubMed ID: 27743938
[No Abstract] [Full Text] [Related]
7. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.
Tran DC; Colevas AD; Chang AL
JAMA Dermatol; 2017 Jan; 153(1):92-94. PubMed ID: 27784038
[No Abstract] [Full Text] [Related]
8. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic.
Kang SP; Gergich K; Lubiniecki GM; de Alwis DP; Chen C; Tice MAB; Rubin EH
Ann Oncol; 2017 Jun; 28(6):1388-1398. PubMed ID: 30052728
[No Abstract] [Full Text] [Related]
9. Apocrine carcinoma and apocrine metaplasia.
Yates AJ; Ahmed A
Histopathology; 1988 Aug; 13(2):228-31. PubMed ID: 3169692
[No Abstract] [Full Text] [Related]
10. Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy.
Yen CC; Su HC; Chu CY; Lai SJ; Yan JJ; Su WP; Su WC
Lung Cancer; 2018 Jun; 120():149-151. PubMed ID: 29681404
[No Abstract] [Full Text] [Related]
11. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
12. Primary apocrine adenocarcinoma of the axilla.
Kathrotiya PR; Bridge AT; Warren SJ; Do H; Klenk AS; Xu LY; Mathur AN
Cutis; 2015 May; 95(5):271-4, 281. PubMed ID: 26057510
[TBL] [Abstract][Full Text] [Related]
13. Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment.
Bender C; Dimitrakopoulou-Strauss A; Enk A; Hassel JC
Ann Oncol; 2016 Jul; 27(7):1353-4. PubMed ID: 26951629
[No Abstract] [Full Text] [Related]
14. Perianal apocrine adenocarcinoma arising in a benign apocrine adenoma; first case report and review of the literature.
MacNeill KN; Riddell RH; Ghazarian D
J Clin Pathol; 2005 Feb; 58(2):217-9. PubMed ID: 15677547
[TBL] [Abstract][Full Text] [Related]
15. Primary apocrine adenocarcinoma with neuroendocrine differentiation occurring on the pubic skin.
Sugita K; Yamamoto O; Hamada T; Hisaoka M; Tokura Y
Br J Dermatol; 2004 Feb; 150(2):371-3. PubMed ID: 14996118
[No Abstract] [Full Text] [Related]
16. Dermoscopy of apocrine adenocarcinoma of the axilla.
Maronese CA; Passoni E; Nazzaro G
Clin Exp Dermatol; 2022 Feb; 47(2):434-436. PubMed ID: 34510512
[No Abstract] [Full Text] [Related]
17. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
[No Abstract] [Full Text] [Related]
18. Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.
Gong J; Robertson MD; Kim E; Fakih M; Schrock AB; Tam KW; Burugapalli B; Monjazeb AM; Hendifar AE; Hitchins M; Klempner SJ; Cho M
Clin Colorectal Cancer; 2019 Dec; 18(4):307-309. PubMed ID: 31563511
[No Abstract] [Full Text] [Related]
19. Bilateral axillary apocrine nevi--a case report.
Amonkar GP; Amonkar PP; Rege JD
Indian J Pathol Microbiol; 2005 Jan; 48(1):22-3. PubMed ID: 16758779
[TBL] [Abstract][Full Text] [Related]
20. Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti-PD-1.
Thomas S; Laino A; Sturm R; Nufer K; Lambie D; Shepherd B; Atkinson V; Adams L; Soyer HP; Schaider H
J Eur Acad Dermatol Venereol; 2018 May; 32(5):e176-e177. PubMed ID: 29114959
[No Abstract] [Full Text] [Related]
[Next] [New Search]
